Abstract: Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease. Epidemiological projections for the global incidence of PD indicate that the number of people with PD might approach 12 million by 2040 (Adrissi and Fleisher, 2022). PD clinical symptoms include bradykinesia, resting tremors, rigidity, and non-motor symptoms such as depression, autonomic dysfunctions, sensory impairments, and sleep disruptions. The neuropathologies of PD are the continuous loss of dopaminergic neurons in the middle brain substantia nigra pars compacta and the accumulation of Lewy bodies which are mainly composed of fibrillar α-synuclein aggregates in neuronal somata. There is growing evidence showing that autophagy is a critical avenue for regulating PD pathogenesis. In 2004, mutant α-synuclein blocked chaperone-mediated autophagy (CMA) demonstrated the first connection between CMA malfunction and PD (Cuervo et al., 2004).